Introduction
initial PP course, earlier conversion to a SP course, as well as earlier reaching of significant disability endpoints. Onset at age 40 and 50 years doubled and tripled, respectively, the risk of converting earlier to SPMS, compared to onset at age 20 years. 9 Interestingly, age of onset only affected time to onset of progression, while times to disability endpoints from progression onset were similar among different age groups. 9 The onset of MS is infrequent and atypical after 50 years (late-onset multiple sclerosis (LOMS)) and more so over 60 years (very late-onset multiple sclerosis (VLOMS)). VLOMS is very rare, with a reported prevalence of 0.45%-0.8% among MS cohorts studied. 10, 11 In a study of 111 VLOMS patients, Bermel et al. 12 reported that over a 5-year period, 8% remained categorized as clinically isolated syndrome (CIS), 33% relapsing-remitting (RR), 23% converted to SP, while 32% presented as PP. The most common initial clinical presentation was acute partial transverse myelitis (41%), followed by progressive myelopathy (31%). 12 The percentage of female patients is lower in the LOMS (65.0%) and the VLOMS (61.4%) groups in comparison with early adult-onset MS (74.0%). 13 VLOMS patients are more likely to have motor and coordination symptoms at onset and less likely to have visual or sensory symptoms. 13 Longer delays in time between symptom onset and diagnosis in older populations are also associated with superimposed cardiovascular comorbidities. 14 PwMS experience disability progression at varying rates, possibly as a consequence of dissimilar underlying pathological processes, different neural reserves, or variable individual ability to repair often related to complex genetic and/or environmental interactions. 15, 16 Previous studies suggested that disease course and disease duration are the strongest predictors for disability progression in MS. 17 However, prospective data suggest that older age is the only linear predictor with a strong relationship to greater disability. 18
Effects of age on MS pathology
The acute multifocal recurrent bouts of CNS inflammation in MS, as classically evidenced by clinical relapses and new lesional magnetic resonance imaging (MRI) findings, can explain the cycle of acute symptom onset followed by recovery in RRMS. However, a superimposed neurodegenerative process can be identified even in early stages of the disease causing irreversible clinical neurological deficits which correlated best with T1 "black holes" and volume loss on MRI. 19 Neuropathological studies demonstrate that axonal degeneration and neuronal loss, the hallmarks of progressive disease, correlated only mildly with focal white matter lesion volume-a measure of the inflammatory process. Moreover, diffuse axonal pathology in normal-appearing white matter and massive cortical demyelination have been observed in cases with only few white matter plaques, indicating that the two processes are at least partly independent. 19 The tissue loss due to MS results in a 0.7%-1% loss of brain volume per year in average PwMS, compared to 0.1%-0.3% loss per year from normal aging in healthy subjects. 20 Key elements of MS neurodegeneration that go on to outweigh the inflammatory process in the progressive stage of the disease consist of microglia activation, mitochondrial dysfunction, oxidative injury, and age-related iron deposition. 21 With aging, the CNS accumulates iron due to increased expression of the ferritin protein in oligodendrocytes and microglia. This increases the intracellular accumulation of ferrous iron (Fe 2+ ) that gets catalyzed to ferric iron (Fe 3+ ) and causes oxidative stress and cell death, contributing toward neurodegeneration. 22 Furthermore, in the presence of CNS inflammatory processes as seen in MS, more deposition of iron occurs through increased iron-rich macrophage migration, free radical production, and cell death. Both brain susceptibility-weighted imaging and histochemical studies suggest that iron accumulation is an important feature of MS lesion formation. The increased iron accumulation is reportedly due to the destruction of iron-rich oligodendrocytes that experience phagocytosis or are sequestered by microglia or macrophages. 23 As disease progresses with advancing age, repair, remyelination, and other physiological functions become less robust. Animal models have shown that while oligodendrocyte precursor cell (OPC) recruitment toward lesions remains intact, differentiation into myelinating oligodendrocytes decreases with age. 24 In experimental models, aged rats demonstrate a slower and less effective remyelination process compared to young rats. 24 Similarly, elderly humans also showed reduced remyelinating capabilities. 24, 25 There are multiple hypotheses to explain this finding, including intrinsic characteristics that pre-determine maturation and aging of OPCs irrespective of extrinsic factors, and epigenetic changes known to occur during aging. 24 Newbould et al. measured magnetized transfer ratio (MTR) activity by MRI and compared two age cohorts after correcting for disease duration and lesion load. MTR is a reliable measure of macromolecule exchange in parenchymal tissue and an indirect measure of myelin status. 26 The age cohort comparison demonstrated a significant decrease in MTR in white matter lesion sites in MS patients aged 45-60 years when compared to PwMS between ages 25 and 35 years. 27 These findings suggest that aging modifies the tissue response to inflammatory injury. Furthermore, imaging studies suggest that during the fourth decade of life, myelination of the compact white matter slows and ceases in parallel with progressive white matter degeneration. 28 Because these age-related changes in myelination coincide with approximately the average age at which PwMS reach progression (mean age: 38-45 years), 8, 29 it has been proposed that the loss of remyelinating capacity with aging contributes to this transition; 8 hence, MS may be a disorder of a single stage, with an apparent shift in phenotype driven not by a fundamental change in pathology but by age-related changes. 9, 29 The immune system in aging population Another feature of aging is a chronic, systemic lowgrade inflammation ( Figure 1 ) influenced by chronic antigenic stimulations, such as infections (i.e. Epstein Barr virus (EBV) and cytomegalovirus (CMV)) and a general increase in the production of pro-inflammatory cytokines and inflammatory markers ("inflammaging"). 30 Chronic CMV infection is considered a major player in immunosenescence. 31, 32 Furthermore, high serological levels of pro-inflammatory mediators like cytokines (including interleukin 6 (IL-6)), C-reactive protein (CRP), and a decrease in important minerals such as zinc (Zn) 33 seem to be contributors toward unhealthy aging. 32 Altered or unbalanced immune responses are responsible for the development of many age-related diseases including cardiovascular conditions, 34 autoimmune diseases, cancers, and increased susceptibility to bacterial and viral infections. Additionally, there is reportedly an alteration in the distribution and functionality of CD4+ T-regulatory cells with immune system senescence. An increase in peripheral CD4+ CD25 highFoxP3+ T-regulatory cells was found in the aging population. However, it remains unclear whether this is an age-related immune dysfunction or a defense response. An alteration in these cells may lead to an overall increase in autoimmune neuroinflammation. 35 The already dysregulated immune system in PwMS may cause these aging pathologies to appear at an earlier age, thus driving the transition from an RR to SP phenotype. 36 
Disease comorbidities and age-related pathology in MS patients
Determining the cause of worsening symptoms in the older MS population is challenging as it is often difficult to differentiate between the normal aging process, diseases that are common in old age, such as Alzheimer's disease (AD) or Parkinson's disease, or an intensified degenerative/inflammatory process directly related to MS disease progression. Often times, it may be a combination of these factors that results in symptom worsening. This section deals with common disease comorbidities that can arise due to these factors.
Mobility
In a study of 2156 PwMS comparing demographic, clinical, and healthcare characteristics of those over and under 65 years, disability was significantly higher in older versus younger patients. A higher percentage of PwMS over 65 years required a cane or bilateral support to walk 25 ft or were wheelchair/scooter dependent or bedridden. 4 In a study of 53 elderly PwMS (mean age: 73 years), nearly all reported problems with mobility. 37 Mean Expanded Disability Status Scores (EDSS) were reportedly above 6.0 (requiring assistance) in 96.2% of patients, while 69.8% required wheelchairs for their mobility. Because of their health condition, 56.6% of the respondents were reportedly unable to leave their flat or house and only 15.1% were able to use public transportation. Problems with spasticity, despite antispasmodic medication, occurred in 45.5% of patients. 37 About 56% of these patients reported pain due to spasticity.
There is burgeoning interest in falls, consequences of falling, and predictors of falls in PwMS 38 as risks and consequences are different for PwMS versus healthy persons of the same age and sex. About 70% of PwMS aged 18-50 years experienced a fall in a given year, and these patients were more likely to sustain an injury from falling compared to their healthy counterparts 39 due to higher prevalence of osteoporosis and fractures being reported in PwMS. 40 Disability levels, progression of disease, walking speed, use of assistive devices (recurrence of falls is higher for those who do not use assistive devices 38 ), and cognitive status are strongly associated with risk of falling. 41, 42 The strong relationship of quality of life (QOL) and activities of daily living (ADLs) to fear of falling 43 as well as risk and injury warrants further research to expand on prevention measures, especially in elderly PwMS. infectious (CMV, EBV, etc.) and non-infectious (environmental and endogenous free radicals (ROS)) stimuli. Prolonged release of IL-6, IL-1β, and TNF-α causes a low-grade chronic inflammation affecting various organs and increasing risk of cancer, increases C-reactive protein (CRP) release from liver, and increases production of auto-antibodies due to increased IL-6 signaling. Prolonged stimulation causes exhaustion and weakening of adaptive immunity, thus reducing the ability to fight and clear infections that persist to further perpetuate the cycle along with free radicals (ROS) released due to the inflammatory process.
Psychological and cognitive problems
The previous section shows that ambulation and other physical capacities decline more rapidly in the aged MS patient. Likewise, in the psychological realm, MS-associated psychological symptoms occur more frequently in the elderly as compared to younger patients. Within an elderly MS patient group (n = 53; mean age: 73 years), 52.8% reported having frequent depressed feelings and moods, and 30.2% had suicidal ideation. 37 Interestingly, while depression and fatigue remain common in older-aged MS patients, the prevalence of anxiety actually decreases. 44 Cognitive impairment is usually identified in up to 40%-60% of patients on cross-sectional diverse MS cohorts, 45 and slowed cognitive processing speed and episodic memory are the most common deficits. In a cross-sectional study of 245 MS patients and 188 healthy controls, subjects were grouped into five age cohorts. The analysis examined the effects of age and MS on cognitive slowing, and there was no group by age interaction, suggesting that the effects of aging on processing speed are similar for healthy persons and PwMS. 46 This study examined only measures of cognitive processing speed and not language or memory. An important question for future research will be to determine whether the MS neuropsychological profile changes with age. After the age of 65 years, the prevalence of aging-related, amnestic mild cognitive impairment and AD increases in the general population. Rapid forgetting and dysnomia are hallmark signs of these conditions and are rarely seen in MS. In one cross-sectional group comparison, differences between MS-associated cognitive disorder and patients with AD were specifically in recognition memory, which was low in AD and normal in MS. 47 One interpretation of the result would be that rapid forgetting and memory retrieval defects are unique to AD and thus may steer the clinician toward diagnosing new-onset AD in an elderly MS patient. It is not known whether MS poses an additional risk factor for AD, and further studies should be targeted at investigating this relationship.
ADL and social support Among 53 elderly PwMS (mean age: 73 years, range: 65-92 years), 22.6% were reportedly unable to take their daily medication out of the box or bottle without getting help. For taking a meal, nearly one-third of the patients always required help from other persons. Only 28 of 53 patients were able to go to the lavatory without being assisted, and 20.8% of them reported being able to take a shower or a bath independently. Because of their impairments in daily self-care, in the same group, 86.8% required aid from professional caregivers. 37 A separate study comparing similar variables in older and younger PwMS, however, showed that although a higher percentage of the older respondents (85% of 169 vs 70% of 1987) needed help from a person or assistive device with ADL or instrumental ADL, no significant differences were noted for eating, managing finances, preparing meals, or doing housework between the two age groups. 4 Additionally, the importance of social support, need for listening, and words of emotional support have been expressed by elderly PwMS, particularly those widowed or living alone as one-third of them (n = 27, age range: 55-81 years) in a study reported relying on their neurologist/physician for social support although no comparison with younger PwMS was made in this study. 48 Bowel and bladder dysfunction Bowel and bladder dysfunctions are frequently related to MS. A higher percentage of older PwMS reported bladder and bowel problems compared to younger patients. 4 The cause of worsening of these symptoms is difficult to establish (MS vs aging), and more specific evaluations performed by urologists and/or gastroenterologists may be necessary for a more appropriate therapy. Bladder problems include, but are not limited to, increased frequency, difficulty in emptying with increased residual volume, and incontinence. 37 Bladder infections are often the cause of acute worsening of symptoms in MS patients that result in hospitalization, therefore underlining the importance of appropriate diagnosis and therapy. Bowel concerns are usually related to constipation but sometimes can also include incontinence episodes. Bowel and bladder incontinence are often cited as most frequent dysfunction along with cognitive dysfunction in PwMS who reside in nursing homes. 49 
Monitoring aging MS population
The outcome measures often used to assess MS patients may not be sufficient or specific to the problem encountered by the aging PwMS. A recent cross-sectional study evaluated a cohort of 346 MS patients enrolled in the New York State Multiple Sclerosis Consortium (NYSMSC), mean age of 67.7 ± 5.5 years with mean duration of symptoms being 29.9 ± 10 years. The cohort was followed for an average of 5.9 ± 3.2 years and had repeated yearly evaluation using EDSS along with LIFEware, 50 (p < 0.001), "climbing stairs" (p < 0.001), "standing for ⩾30 minutes" (p = 0.003), "difficulty driving" (p < 0.001), and "bowel incontinence" (p = 0.031) deteriorated over time similarly in the two groups, supporting the importance of using PROs as well as the need for better and sensitive outcome measures for the elderly MS population in particular. 51 
Vascular comorbidities
Cardiovascular comorbidities are known to increase with age. Marrie et al. 52 reported that although vascular comorbidities such as hypertension, diabetes, and hyperlipidemia occur in PwMS at a rate similar to the general population, they have been shown to significantly increase the risk of ambulatory disability by 1.5-fold, as well as decrease time from diagnosis to ambulatory disability by about 6 years when compared to patients without vascular comorbidities. Furthermore, in patients with two or more vascular comorbidities, the risk of ambulatory disability raised more than twofold. 36 Cardiovascular risk factors were also associated with decreased gray matter and cortical volumes, as well as with increased lesion burden. 34 Weinstock-Guttman et al. showed that worsening disability was associated with higher levels of low-density lipoprotein (LDL) cholesterol, total cholesterol, and triglycerides. Higher levels of high-density lipoprotein (HDL) cholesterol were reportedly associated with lower levels of acute neuro-inflammatory activity. 53 Interestingly, a recent evaluation of cause of death of PwMS based on NARCOMS data identified that although cancer and cardiovascular causes were more frequently the causes of death associated with increasing age, the cohort of MS subjects had a lower mortality from cardiovascular disease and cancer compared to the US elderly population. 54 The effect of disability on mortality was roughly equivalent to the effect of aging on mortality.
Polypharmacy
Attempts to treat these comorbidities with various combinations of medications often result in polypharmacy (⩾5 drugs). Thelen et al. 55 showed that polypharmacy in PwMS was associated with increased fatigue, subjective cognitive impairments, as well as poorer performance on a prospective memory test after controlling for age, disability level, duration of MS diagnosis, and number of comorbid health conditions.
Thus, when dealing with fatigued and cognitively impaired PwMS, reviewing their current medications and eliminating one or more drugs may be more efficient in some cases rather than adding more to address these concerns. The UK National Institute of Health and Care Excellence (NICE) recommends conducting a comprehensive review of all aspects of care of PwMS at least once a year, which includes a review of their current drugs. 56 Use of DMTs in elderly population represents another uncertain topic. The benefit is not clear as most elderly patients are already in the SP stage without clear relapses for which no DMT has yet proven beneficial. Moreover, as most phase-3 randomized controlled trials have explicitly excluded patients over 60 years, the efficacy and safety use of immunomodulatory, and especially immunosuppressive therapies in the elderly, are unknown. A recent Canadian study evaluating the effect of interferon (IFN) in older relapsing-onset MS patients found no significant benefit of IFN-β therapy on delaying disability progression. 57 In some cases, discontinuation of DMTs may be an appropriate step, although no sufficient data are available to support or refute this recommendation.
Conclusion
This review points to important facts our society has to consider: the mean age of the MS population is rising, and an increased number of elderly PwMS are expected to be evaluated. Clinicians should be aware of the effects of older age of onset and advancing age on the clinical presentation and course of MS. In particular, one must understand how to distinguish normal aging phenomena from worsening MS and to identify other neurological disorders that are common in aging, but may nevertheless mimic some of the many symptoms of MS. In this review, we have identified key symptom domains that are likely to overlap with aging effects, among various other factors influencing disease course and their implications from a healthcare standpoint. A multidisciplinary approach toward care of elderly PwMS is required, including physical therapists, urologists, orthopedic, and geriatric specialists. Care-providers should have a high degree of suspicion for depression, anxiety, and fatigue in view of their prevalence, concurrence, and associated ill-effects. PwMS should be routinely screened for suicidal ideation and intent. 37 Problems with mobility, prevention of falls, social support, and ADLs and their implications on overall QOL should not be overlooked.
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